Genetic Testing Medicare proposed new rule
WASHINGTON — Patient groups and drug manufacturers say a proposed rule from the Center for Medicare and Medicaid Services would dramatically restrict coverage of genetic tests for patients covered by those programs — a move which may specifically impact patients deciding between various cancer treatments.
The rule, expected to be finalized next week, stipulates that CMS only cover next-generation sequencing (NGS) tests approved by the Food and Drug Administration. That would leave a small subset of existing diagnostic tools — including the FoundationOne, Oncomine Dx, and Illumina — available to Medicare beneficiaries.
Source: STAT News
Comments
-
Genetic Testing
Good point. Decrease competition and decrease coverage by tightening the criteria for coverage. Anyone who is covered by Medicare should learn how to search the Local Coverage Determinations and National Coverage Determinations. Medicare contracts with commercial insurance companies by geographic region to research and then do the administration of these medical coverage determinations . Most people don’ t know anything about them.
0
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 120.8K Cancer specific
- 2.8K Anal Cancer
- 440 Bladder Cancer
- 304 Bone Cancers
- 1.6K Brain Cancer
- 28.4K Breast Cancer
- 388 Childhood Cancers
- 27.8K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.1K Gynecological Cancers (other than ovarian and uterine)
- 12.8K Head and Neck Cancer
- 6.3K Kidney Cancer
- 660 Leukemia
- 779 Liver Cancer
- 4.1K Lung Cancer
- 5K Lymphoma (Hodgkin and Non-Hodgkin)
- 233 Multiple Myeloma
- 7.1K Ovarian Cancer
- 48 Pancreatic Cancer
- 485 Peritoneal Cancer
- 5.2K Prostate Cancer
- 1.2K Rare and Other Cancers
- 531 Sarcoma
- 706 Skin Cancer
- 643 Stomach Cancer
- 190 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.8K Uterine/Endometrial Cancer
- 6.3K Other Discussion Boards